Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment

被引:3
|
作者
Wang, Chuanlin [1 ,2 ]
Gao, Pengning [1 ,2 ]
Xu, Jiali [1 ,2 ]
Liu, Shanling [1 ,2 ]
Tian, Wenda [2 ,3 ]
Liu, Jiayu [4 ]
Zhou, Lan [1 ,2 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Dept Clin Nutr, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[2] Yunnan Canc Ctr, Kunming, Yunnan, Peoples R China
[3] Kunming Med Univ, Yunnan Canc Hosp, Dept Gynecol, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[4] Anhui Med Univ, Key Lab Environm Toxicol Anhui Higher Educ Inst, Sch Publ Hlth, Dept Toxicol, Hefei, Anhui, Peoples R China
关键词
phytochemicals; ovarian cancer; PARP; BRCA; PARP inhibitors; ANTIOXIDANT DEFENSE SYSTEM; ENDOTHELIAL DYSFUNCTION; DNA-REPAIR; DAMAGE; KEAP1; CROCIN; TUMORS; CELLS; NRF2; ROS;
D O I
10.3389/fphar.2022.1078303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ovarian cancer is among the most common malignant tumors in gynecology and is characterized by insidious onset, poor differentiation, high malignancy, and a high recurrence rate. Numerous studies have shown that poly ADP-ribose polymerase (PARP) inhibitors can improve progression-free survival (PFS) in patients with BRCA-mutated ovarian cancer. With the widespread use of BRCA mutation and PARP inhibitor (PARPi) combination therapy, the side effects associated with BRCA mutation and PARPi have garnered attention worldwide. Mutations in the BRCA gene increase KEAP1-NRF2 ubiquitination and reduce Nrf2 content and cellular antioxidant capacity, which subsequently produces side effects such as cardiovascular endothelial damage and atherosclerosis. PARPi has hematologic toxicity, producing thrombocytopenia, fatigue, nausea, and vomiting. These side effects not only reduce patients' quality of life, but also affect their survival. Studies have shown that natural phytochemicals, a class of compounds with antitumor potential, can effectively prevent and treat the side effects of chemotherapy. Herein, we reviewed the role of natural phytochemicals in disease prevention and treatment in recent years, including sulforaphane, lycopene, catechin, and curcumin, and found that these phytochemicals have significant alleviating effects on atherosclerosis, nausea, and vomiting. Moreover, these mechanisms of action significantly correlated with the side-effect-producing mechanisms of BRCA mutations and PARPi. In conclusion, natural phytochemicals may be effective in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Cavallin, Francesco
    Grego, Andrea
    Falci, Cristina
    Nardin, Margherita
    Mammano, Enzo
    Lai, Eleonora
    Torri, Valter
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [2] Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer
    Yunokawa, Mayu
    ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
  • [3] PARP inhibition in BRCA-mutated breast and ovarian cancers
    Chan, Stephen L.
    Mok, Tony
    LANCET, 2010, 376 (9737): : 211 - 213
  • [4] SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer
    Mithun Ghosh
    Min Sil Kang
    Nar Bahadur Katuwal
    Sa Deok Hong
    Seong Min Park
    Seul-Gi Kim
    Seung Ryeol Lee
    Yong Wha Moon
    Cell Death & Disease, 16 (1)
  • [5] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [6] Progress in BRCA-Mutated Ovarian Cancer
    Spriggs, David R.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2567 - 2568
  • [7] PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
    Yan, Feifei
    Jiang, Qi
    He, Mengye
    Shen, Peng
    FUTURE ONCOLOGY, 2021, 17 (18) : 2381 - 2393
  • [8] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [9] Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer
    Kim, Yoo-Na
    Shim, Yeeun
    Seo, Jieun
    Choi, Zisun
    Lee, Yong Jae
    Shin, Saeam
    Kim, Sang Wun
    Kim, Sunghoon
    Choi, Jong Rak
    Lee, Jung-Yun
    Lee, Seung-Tae
    CLINICAL CANCER RESEARCH, 2023, 29 (14) : 2725 - 2734
  • [10] Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer
    Yoo-Na Kim
    Yeeun Shim
    Jieun Seo
    Zisun Choi
    Yong Jae Lee
    Saeam Shin
    Sang Wun Kim
    Sunghoon Kim
    Jong Rak Choi
    Jung-Yun Lee
    Seung-Tae Lee
    李贺
    肿瘤药学, 2023, 13 (06) : 644 - 644